Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group. Joly V, et al. Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13. doi: 10.1128/AAC.46.6.1906-1913.2002. Antimicrob Agents Chemother. 2002. PMID: 12019107 Free PMC article. Clinical Trial.
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. Among authors: joly v. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Among authors: joly v. Clin Infect Dis. 2003 Dec 1;37(11):1517-26. doi: 10.1086/379070. Epub 2003 Oct 29. Clin Infect Dis. 2003. PMID: 14614675
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, Delarue S, Yeni P, Brun-Vezinet F. Joly V, et al. Antimicrob Agents Chemother. 2004 Jan;48(1):172-5. doi: 10.1128/AAC.48.1.172-175.2004. Antimicrob Agents Chemother. 2004. PMID: 14693536 Free PMC article.
215 results